Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization.

Likic, Robert; Dear, James W; Lewis, Lionel D

Likic, Robert; Dear, James W; Lewis, Lionel D.

Afiliação

Likic R; University of Zagreb Medical School, Zagreb, Croatia.
Dear JW; Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, Clinical Hospital Centre Zagreb, Zagreb, Croatia.
Lewis LD; Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Br J Clin Pharmacol ; 88(12): 5060-5063, 2022 12.

Article em En | MEDLINE | ID: mdl-36206769

Assuntos

Inibidores de Checkpoint Imunológico; Neoplasias; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Neoplasias/tratamento farmacológico; Ipilimumab; Resultado do Tratamento; Biomarcadores; Protocolos de Quimioterapia Combinada Antineoplásica

Palavras-chave

checkpoint inhibitors; dose optimization; ipilimumab; nivolumab; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Limite: Humans Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Croácia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google